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Human pharmacokinetics and CSF penetration of clavulanic acid
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University of Zurich and Federal Institute of Technology, CH-8091 Zurich, Switzerland
Clavulanic acid, a product of Streptomyces clavuligerus with /Mactam structure,
is a potent inhibitor of several /Mactamases. To study its pharmacokinetic and
CSF penetration in patients without meningeal inflammation, a single oral dose of
250 mg of clavulanic acid was given to 21 patients. One patient was studied in a
multiple dose schedule. Fifteen of these 21 patients had a diagnostic lumbar
puncture and 3 neurosurgical patients had a continuous CSF drainage. Serum and
urine concentrations of clavulanic acid were available from 22 patients. The mean
peak serum concentration was 4'3 mg/1 and individual peak serum concentrations
ranged from (M-9-5 mg/1 between 40 and 60 min after ingestion of clavulanic
acid. Urinary recovery between 300 and 400 min ranged from 0"8-54'3% of the
administered dose. The mean absorption half life was 0"26 h and the mean elimin-
ation half life was 0'9 h. Considerable degradation of clavulanic acid occurred in
vitro at 37"C. In pooled human serum, phosphate buffer pH 7 and 5, an hourly
loss of activity of about 10,7 and 10% respectively, was observed.
Introduction
Clavulanic acid, a product of Streptomyces clavuligerus, which structurally
resembles the penicillin nucleus, is one of the first compounds with /Mactamase
inhibiting properties (Brown et al., 1976; Reading & Cole, 1977). It has only weak
broad spectrum antibacterial activity but it was shown that it acts as an irreversible
inhibitor of many clinical important /Mactamases of Richmond types II-V (Neu &
Fu, 1978) and protects /Mactamase susceptible broad spectrum penicillins from
hydrolysis by /Mactamases (Paisley & Washington, 1978; Dumon et al., 1979; Wust
&Wilkins, 1978; Reeves, Bywater& Holt, 1978).
Certain strains of the most common pathogens of bacterial meningitis in children,
Haemophilus influenzae, are resistant to aminopenicillins due to the production of a
^-lactamase (Howard, 1977; Turk, 1978, Thomas et al., 1974). It could be demon-
strated, that concentrations of 1-5 mg/1 of clavulanic acid regularly rendered such /?-
lactamase producing ampicillin resistant strains sensitive to blood concentrations of
broad spectrum penicillins attainable in vivo (Reeves, Bywater & Holt, 1978). This
could be of potential importance in the future treatment of//, influenzae meningitis
due to /Mactamase-producing organisms.
There are only few data available on human pharmacokinetics of clavulanic acid
after oral administration and no data on penetration of clavulanic acid into human
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cerebrospinal fluid (CSF)- Therefore, our study was designed (1) to report on
pharmacokinetics of clavulanic acid after oral application of 250 mg, (2) to study the
entry of clavulanic acid into CSF of human adults without meningeal inflammation
and (3) to obtain some information on the in-vitro stability of clavulanic acid.
Material and methods
Materials
Clavulanic acid capsules (BRL 14151, batch CT 9047) containing 125 mg of the
sodium salt, clavulanic acid reference standard and benzylpenicillin laboratory
standard were kindly supplied by Beecham Pharmaceuticals, England. The assay
organism Klebsiella pneumoniae designated BRL 1003 was obtained from Beecham
Pharmaceuticals.
Patients
Twenty-two patients (15 male and 7 female) of the Departments of Neurology,
Neurosurgery and Medicine of the University Hospital of Zurich took part in our
investigation. Informed consent according to institutional policies was obtained
from each participant. Eighteen of these 22 patients were studied for CSF pene-
tration of clavulanic acid. Of the 18 patients, 3 had a continuous CSF drainage
(Cocchi drainage) after a neurosurgical procedure. In the remaining four patients
only serum and urine concentrations of clavulanic acid were measured.
Dosage
After fasting for at least 4 h, 18 subjects received a single dose of 250 mg of
clavulanic acid taken with 150 ml of water. In 3 subjects, who were unable to take
capsules, the content of two capsules was dissolved in 150 ml water and immediately
taken by mouth or gastric tube. An additional patient received the dissolved drug in
a multiple dose schedule of 5 times 250 mg of clavulanic acid every 6 h. No food
intake was allowed at least for 1 h after dosing.
Sampling
In the single dose studies, blood samples were drawn prior to, 0 3 , 07 , 1 and 15 h
after administration and simultaneously to CSF specimen collection. Additional
samples were drawn at 2, 3,4 and 6 h after ingestion of clavulanic acid. In the three
patients with continuous CSF drainage CSF specimens were drawn simultaneously
to the blood samples prior to, 0 3 , 0 7 , 1, 15,2 ,4 and 6 h after administration of the
drug.
Sampling schedules of blood and CSF in the neurosurgical patient studied in the
multiple dose regimen are indicated in Figure 8. Urine collection periods are shown
in Figure 5(b).
Blood was allowed to clot at room temperature and then centrifuged at +4'C.
Serum-, urine- and CSF-specimens were immediately frozen and stored in liquid
nitrogen.
Routine CSF examination including cell counts and measurement of protein
concentration showed elevated CSF protein concentrations with 40, 62 and
> 100 mg/100 ml (upper l imi t^ 34 mg/100 ml) in 3 of 15 patients, who underwent
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a lumbar puncture. In all three cases CSF cell counts remained within normal
range (<^5/mm3). In two of the three neurosurgical patients with continuous CSF
drainage routine CSF analysis was done. In both cases CSF protein concentrations
were elevated (198 and 310 mg%, respectively), and in one of these two patients cell
count was above the normal range (167/mm3).
Assay methods
Serum-, urine- and CSF-specimens were assayed within 1 week with a slightly
modified large plate agar diffusion method (Bennett et al., 1966). The assay method
for clavulanic acid was developed by Beecham Research Laboratories. Benzyl-
penicillin was added to CLED agar (Oxoid, code CM 301) to achieve a final concen-
tration of 5 mg/1. Due to the inactivation by clavulanic acid of the /Mactamase
produced by the assay organism Klebsiella aerogenes A, the benzylpenicillin was
protected from enzymatic degradation. Thus, the benzylpenicillin was then able to
inhibit the growth of the assay organism producing zones dependent on the
concentration of the inhibitor. Concentrations of clavulanic acid in serum could be
measured within the range of 062-10 mg/1, in CSF and urine within the range of
0" 16-2-5 mg/1. Serum, CSF and urine standards were prepared on each study day
from pooled, antibiotic free human serum, human CSF and 005 M phosphate buffer
pH 7, respectively.
Stability studies
The time, medium and temperature dependent loss of activity was best described by
an exponential decline. Hourly degradation rates were calculated by regression
analysis.
Two series of three different concentrations of clavulanic acid were prepared by
twofold dilution steps in pooled antibiotic free human serum, 005 M phosphate
buffer pH 5 and pH 7, respectively. Each sample was kept at 37"C, serum samples
additionally at room temperature. The degradation process was interrupted by
freezing at — 196'C after 0, 1,2,4,6 and 8 h. The assay was performed within 1 week
as described above. For each study condition mean values and standard deviations of
the degradation rate were calculated from all six results.
Pharmacokinetic analysis
Serum concentration time courses of the 14 patients with at least five measurable
serum levels were analysed using a one-compartment open model (Figure 1)
incorporating the following four parameters: absorption lag time (rG|) total volume
of distribution (VD) and the first-order rate constants for absorption (/cj and
elimination (kj (Gibaldi & Perrier, 1975). Serum and CSF kinetics in the three
patients with continuous CSF drainage were fitted using a linear multicompartment
model (Figure 2) incorporating six variable parameters (TGI, k^, kt as defined above
and tcsp = CSF lag time (see below), Q = transfer constant (liters/h), VB = volume of
distribution minus ^CSF)- TWO additional parameters, the degradation constant of
CSF A:D= 10% h and the volume of CSF FCSF = O-135 1 (Wissenschaftliche Tabellen-
Geigy, 1977) were kept constant.
The following differential equations define the model:
(1)
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ionFigure 1. One compartment open model. Gl = gastrointestinal tract; TGI = gastrointestinal absorption
lag time (min); k& = absorption rate constant (A"1); /ke = elimination rate constant (/r1); KD = volume of
distribution (I).
Figure 2. Linear multicompartment model. GI = gastrointestinal tract; XQ\ = gastrointestinal absorp-
tion lag time (min); TCSF = C S F lag time (min); k^ = absorption rate constant (/r1); ^ = elimination rate
constant (/r1); kD = CSF degradation constant (10%/h); KB = volume of distribution minus volume of
CSF compartment (1); KCSF = volume of CSF (0135 1); (? = transfer constant (1/h).
B^ _ K
dt 'Gl
_ Q
(2)
(3)
'CSF
Due to the inhomogeneity of the CSF concentration and the capacity of the drainage
tube, there is a delay (TCSF) between the CSF concentration in the CSF compartment
and the value measured in the outflow of the drainage. This delay was taken into
account by fitting the CSF data not to the time corresponding concentrations of the
model, but to the calculated CSF values of the time (/ — rCSF). All pharmacokinetic
parameters were adapted to the experimental data with a non-linear fitting program
(Metzler, Elfring & McEwen, 1974).
Results and discussion
Stability studies
The time dependent loss of activity followed an exponential function which seems to
be medium-, temperature- and pH-dependent. At room temperature a loss of
42 ± 10 %/h could be observed in serum while at 37"C the mean degradation was
1 1 2 ± 0 1 % / h . To simulate the physiological urine conditions, the in-vitro
degradation was studied at two different pH values in phosphate buffer at 37"C. At
pH 7 the degradation was 6-5 ± 08 %/h (Figure 3), at pH 5 109 ± 19 %/h. These
degradation studies demonstrate, that the sodium salt of clavulanic acid appears to
be relatively unstable, a fact that has to be taken into account in pharmacokinetic
and microbiological evaluations.
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Figure 3. Time dependent loss of activity of clavulanic acid in phosphate buffer pH 7 at 37'C. Two
series (A and B) of three concentrations (2-5 mg/1, 1-25 mg/1, 0-30 mg/1) were analysed to estimate the
hourly degradation rate. Series A, Series B.
Pharmacokinetic study
The mean serum concentration time course after oral administration of 250 mg of
clavulanic acid is shown in Figure 4. At 60 min the serum level averaged
4 3 ± 22 mg/1. The individual peak serum concentrations were reached between 40
and 60 min after ingestion of clavulanic acid and ranged from 0 1 - 9 5 mg/1.
Ball et al. (1980) observed in a single dose pharmacokinetic study a mean peak
serum concentration of 255 mg/1 of clavulanic acid 60 min after oral administration
of 125 mg sodium clavulanate to four volunteers in combination with 250 mg
amoxycillin. If a linear dose response is assumed, our measured serum concen-
trations are comparable to these data. In two patients of the same study who received
250 mg potassium clavulanate, a peak serum concentration of 59 mg/1 could be
detected. A mean peak serum concentration of approximately 6 mg/1 was
2 3 4 5 6
Time(h)
Figure 4. Senim concentrations (X ± S.D.) after oral administration of 250 mg of clavulanic acid.
n = number of patients.
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determined in four fasting volunteers 60 min after oral administration of 250 mg of
potassium clavulanate (Reeves et al., 1980). The published pharmacokinetic data on
the potassium salt of clavulanic acid are insufficient to demonstrate a significantly
improved gastrointestinal absorption.
The observed wide range in peak serum concentrations may be due to a between-
subject variability in gastrointestinal absorption and/or in-vitro degradation. These
striking variations are confirmed by the observation of Hoffler & Dalhoff (1980) who
found peak serum concentrations ranging from 135-4-5 mg/1 after oral adminis-
tration of 250 mg sodium clavulanate.
The terminal serum half life averaged 09 ± 0-5 h (range: 0-6-2-5 h), which is
comparable to most penicillins (Barza & Weinstein, 1976). The terminal serum half-
life of clavulanic acid determined in four volunteers in the above mentioned study
by Ball et al. (1980) averaged 61 min. The absorption rate constant ka averaged
2-6 ± 1-1 h"1 (range: 1 -2-4-7). The lag time between ingestion and appearance of the
drug in the serum (TGI) averaged 0 3 ± 01 h (range: 0-1-0-6), indicating a relatively
fast absorption of the drug. No remarkable differences in the rate of drug absorption
were observed regardless of the form of administration (intact capsules or dissolved
drug).
Urinary excretion after 5 to 67 h ranged from 0-8-54-3% of the administered dose.
Figure 5(a) and (b) show a comparison of peak serum concentrations and the urinary
recovery. In the three patients with peak serum concentrations below 2 mg/1 [A, O,
D, Figure 5(a)], urinary recovery during the first 6 h was less than 5% of the adminis-
tered dose [Figure 5(b)], indicating a very poor absorption in these three patients.
Figure 6 shows the results of the CSF concentrations of clavulanic acid in 15
patients with non-inflammed meninges, who underwent a spinal tap. In seven
patients no clavulanic acid activity was detected, in seven patients CSF concen-
trations were detectable but below the lowest standard concentration (0-16 mg/1) and
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Figure 5. Peak serum concentrations (a) and urinary recovery in % of the administered dose (b) after oral
administration of 250 mg clavulanic acid. Corresponding peak serum concentrations and urinary
recoveries are marked (D, A, O).
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Figure 6. CSF concentrations after oral administration of 250 mg of clavulanic acid. Each symbol
represents a CSF concentration of one patient Detectable amounts of clavulanic acid below the lowest
standard concentration (0-16 mg/l) were extrapolated.
had to be extrapolated and only in one case the observed CSF concentration was
with 02 mg/l within the range of the standards.
There seems to be a lag time between administration and appearance of clavulanic
acid at the site of the lumbar puncture. In all patients except one, who had their
spinal tap within the first 2 h, no clavulanic acid was detected in the CSF, whereas in
all six patients who had CSF taps after 2 h of administration, clavulanic acid activity
was 8% or less of the simultaneous serum concentration.
10-0
• A (CSF)
'"° - A (Serum)
B (CSF)
B (Serum)
Time(h)
Figure 7. Serum- and CSF concentration time curves in two patients (A) and (B) with a continuous CSF
drainage after oral administration of 250 mg clavulanic acid. Data were analysed using a linear multi-
compartment model (Figure 2).
The serum and CSF concentration time courses of the two patients with
continuous CSF drainage, who received a single dose are shown in Figure 7. In both
patients equalization between serum and CSF time curves was attained after
approximately 37 h. Peak CSF concentrations were measured 4 h after ingestion of
clavulanic acid. At that time, CSF concentrations were 2 4 mg/l for patient A and
0 4 for patient B, while the corresponding serum levels were 23 mg/l and 0 3 mg/l,
respectively. In contrast to these two patients, no such equalization was observed
during the first 6 h in a patient with a multiple dose study (Figure 8). This could be
attributed to a lower drug penetration into the CSF.
The discrepancy of these relatively high CSF concentrations in the three neuro-
surgical patients with continuous CSF drainage compared to the findings of a very
poor penetration of clavulanic acid into CSF in patients studied by lumbar puncture
can be explained by differences in the permeability of the blood brain barrier. In the
postsurgical period a derangement of this barrier is a common finding in most
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Figure 8. Serum and CSF concentration time course in one patient with a continuous CSF drainage
studied in a multiple dose scheme. Clavulanic acid concentrations of serum and CSF measured during the
first 6 h were analysed with a linear multi-compartment model (Figure 2). Computer fitted serum
concentration time course; -, computer fitted CSF concentration time course; , computer
fitted CSF concentration time course incorporating an hourly degradation rate of 10%.
patients (Davson, 1967). The elevated protein levels in two of these patients support
this observation. However a better permeability in patients with a disturbed blood
brain barrier need to be confirmed by CSF measurements of clavulanic acid concen-
trations in patients with meningeal inflammation.
Another result of the multiple dose trials is that although a steady state is reached,
measured CSF concentrations are constantly below the corresponding serum values
(Figure 8). A possible explanation for this observation would be a semi-permeable
behaviour of the blood brain barrier. However, pharmacokinetic analysis with a
multicompartment model (Figure 2) is capable of describing this phenomenon
adequately without this hypothesis of a semipermeable behaviour.
Parameters of this model were fitted to the serum- and CSF concentrations of the
first 6 h and subsequently used to simulate the time course of serum and CSF over
the whole study period.
An hourly degradation rate of 10% as an additional route of elimination in CSF
was incorporated into the model according to the loss of activity in pooled human
serum observed in our in-vitro studies. With this procedure, the CSF concentration
time course can be predicted over a longer time period (Figure 8).
The observed difference between measured and predicted serum concentrations
could be due to various factors including an intraindividual variation in absorption
and/or changes in the volume of distribution.
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